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The objective of this study was to determine whether family members of patients with pediatric
multiple sclerosis (MS) have an increased prevalence of autoimmune conditions compared
with controls.
Methods
Data collected during a pediatric MS case-control study of risk factors included information
about various autoimmune diseases in family members. The frequency of these disorders was
compared between cases and controls.
Results
There was an increased rate of autoimmune diseases among family members of pediatric MS cases
compared with controls with first-degree history of MS excluded (OR = 2.27, 95% CI 1.71–3.01, p
< 0.001). There was an increased rate of MS among second-degree relatives of pediatric MS cases
compared with controls (OR = 3.47, 95%CI 1.36–8.86, p = 0.009). TheOR forMSwas 2.64 when
restricted to maternal relatives and 6.37 when restricted to paternal relatives.
Discussion
The increased rates of autoimmune disorders, including thyroid disorders and MS among families
of patients with pediatricMS, suggest shared genetic factors among families with children diagnosed
with pediatric MS.
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Multiple sclerosis (MS) is an autoimmune disorder targeting
the CNS that is most commonly diagnosed in women around
age 30 years.1 An estimated 5% of all MS cases have onset
under age 18 years.2 Multiple genetic and environmental risks
have been identified for MS.1 Studying pediatric MS provides
a unique opportunity to gain insights into the pathophysiol-
ogy and causes of MS because of the relatively fewer number
of irrelevant exposures preceding disease onset and the pos-
sibility that larger exposures result in earlier onset.
Genetic risk factors for pediatric MS have been reported that
overlap with adult MS. These include HLA-DRB1*15:01 and
multiple class III risk variants.3 Several risk factors for autoim-
mune disorders, including genetic variants or vitamin D de-
ficiency, are shared among various conditions, includingMS.4-10
There have been conflicting reports about rates of autoimmune
diseases in families of patients with adult MS.11,12 Data con-
sistently, however, note that MS risk is increased among first-
degree relatives of patients with MS, including children of
parents with MS.13 This study sought to understand the in-
cidence of a history of autoimmune diseases in family members
of pediatric MS cases compared with pediatric controls.
Methods
Participants of this case-control study included children with
MS or clinically isolated syndrome and healthy pediatric sub-
jects recruited at 17 clinics participating as part of a nationwide
study of environmental risk factors in pediatric MS between
November 1, 2011, and July 1, 2017 (R01NS071463, PI
Waubant). Diagnosis and control status was established by the
treating neurologist and confirmed by adherence to published
criteria for pediatric demyelinating disease as determined by a
panel of 3 pediatric MS specialists using the 2010 McDonald
Criteria. Centers obtained institutional review board approval as
well as written informed consent from parents of pediatric
participants and assent as appropriate from children. Criteria
mandated that cases were enrolled within 4 years of symptom
onset. Healthy controls were recruited from primary care, ur-
gent care, or other pediatric clinics at the participating institu-
tions. Eligibility criteria for controls required (1) absence of any
ongoing autoimmune disease (apart from eczema and asthma)
and (2) no history of MS in any immediate, biological family
member. Demographic data including race and ethnicity, con-
sistent with NIH guidelines, were provided by parents of pe-
diatric participants. Standardizedmedical history questionnaires
were completed by patients and families including family au-
toimmune disease history.
All analyses were conducted using SAS 9.4 (SAS Institute;
Cary, NC). Patient characteristics were summarized using
medians and quartiles or counts and percentages as appro-
priate. Chi-squared tests were used to compare reported
family history of autoimmune disease between cases and
controls, for both overall history of any disease and for specific
diseases (e.g., MS).
Logistic regression models were used to test for differences
between cases and controls in reporting a family history of
autoimmune diseases, when adjusting for sex, race, age, eth-
nicity, and mother’s education level. ORs and 95% CIs were
calculated based on the logistic regression models.
The diseases that were found to be significant in the overall
tests were investigated within 5 relative groups: first-degree
relatives, second-degree relatives, parents, maternal relatives,
Table 1 Subject Characteristics









15.6 (12.5, 17.8) 16.0 (14.2, 17.5) 0.196b
Sex 0.052a
Male 290 (40.9%) 175 (35.4%)
Female 419 (59.1%) 320 (64.6%)
Race 0.115a
White 438 (61.8%) 311 (62.8%)
Black 107 (15.1%) 87 (17.6%)
Other 114 (16.1%) 60 (12.1%)
Unknown 50 (7.1%) 37 (7.5%)
Ethnicity <0.001a
Hispanic or Latino 155 (21.9%) 150 (30.3%)
Not Hispanic or Latino 519 (73.2%) 318 (64.2%)
Unknown 35 (4.9%) 27 (5.5%)
Mother’s education level <0.001a
None 40 (5.6%) 51 (10.3%)
High school or associate’s 294 (41.5%) 244 (49.3%)
Bachelor’s or graduate 292 (41.2%) 138 (27.9%)
Unknown 83 (11.7%) 62 (12.5%)
Statistical tests exclude missing or unknown values.
a Chi-squared test of no association.
b Wilcoxon rank-sum test.
Glossary
MS = multiple sclerosis.
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and paternal relatives. The same statistical methods applied to
the overall analyses were implemented in the relative group
analyses. When expected cell counts were less than 5, Fisher
exact tests were performed in place of χ2 tests. A significance
level of 0.05 was used for all analyses.
Data Availability
Deidentified data sets from this study can be made available to
qualified investigators with appropriate ethics/IRB approval.
Data are stored for up to 5 years postpublication.
Results
Participants’ Characteristics
This study included 1,204 participants with 709 controls and
495 cases (37 of which were categorized as clinically isolated
syndrome). The breakdown of cases and controls based on age,
sex, race, and ethnicity is summarized in Table 1. Groups were
well matched except for ethnicity and mother’s education.
Family History of Autoimmune Disorders
Because controls could not have a history of MS in immediate
biological family members (study exclusion criteria), analyses
involving familial MS excluded first-degree relatives. There was
a significant difference in prevalence of a family history of au-
toimmune disease in patients with MS compared with controls
(68.1% vs 49.5%, p < 0.001) (Table 2). The conditions with
significant differences in prevalence between cases and controls
were childhood-onset and adult-onset diabetes, thyroid disor-
ders, rheumatoid arthritis, MS (in non–first-degree relatives),
and systemic lupus erythematosus. Significant differences be-
tween cases and controls were also found for the “other” cate-
gory. Rates of eczema, psoriasis, and bowel disorders did not
differ significantly.With adjusted analyses (adjusted for age, sex,
race, ethnicity, and biological mother’s highest level of educa-
tion), the OR of any family history of autoimmune disease was
2.27 among cases compared with controls (95% CI, 1.71–3.01,
p < 0.001) (Table 3). With adjusted analyses, the OR of any
family history of MS (in non–first-degree relatives) was 4.16
among cases compared with controls (95% CI, 2.57–6.75, p <
0.001) (Table 3). Furthermore, with the adjusted analyses, the
other category of autoimmune diseases lost statistical signifi-
cance while inflammatory bowel diseases were more prevalent
in families of patients with pediatric MS (p = 0.024).
Separate analyses were performed to understand the associ-
ation between family history of autoimmune diseases and
pediatric MS based on which relatives were reported as having
autoimmune diseases. The analysis was performed for several
categories of relatives: all first-degree relatives, just parents,
second-degree relatives, maternal relatives, and paternal rel-
atives. History of MS in pediatric MS patient’s mothers was
excluded from the maternal relative analysis for MS, and
history of MS in patient’s fathers was excluded from the
Table 2 Unadjusted Analyses of Reported Family History
of Autoimmune Disease







Any reported family historya 351 (49.5%) 337 (68.1%) <0.001b
Diabetes: adult onset 211 (29.8%) 221 (44.6%) <0.001b
Diabetes: childhood onset 19 (2.7%) 31 (6.3%) 0.002b
Thyroid disease/Hashimoto
disease/Graves disease
95 (13.4%) 99 (20.0%) 0.002b
Rheumatoid arthritis 66 (9.3%) 77 (15.6%) <0.001b
MSa 29 (4.1%) 68 (13.7%) <0.001b
Atopic dermatitis/eczema 45 (6.3%) 24 (4.8%) 0.271b
Psoriasis 36 (5.1%) 26 (5.3%) 0.892b
Inflammatory bowel disease/
Crohn disease/ulcerative colitis
25 (3.5%) 29 (5.9%) 0.054b
Systemic lupus erythematosus 22 (3.1%) 28 (5.7%) 0.029b
Other autoimmune disease 72 (10.2%) 69 (13.9%) 0.045b
Abbreviation: MS = multiple sclerosis.
Celiac disease, hyperparathyroidism, Sjogren syndrome, rheumatic heart
disease, sarcoidosis, idiopathic thrombocytopenic purpura, vitiligo, mixed
connective tissue disease, scleroderma, pernicious anemia, ankylosing
spondylitis, chronic inflammatory demyelinating polyneuropathy, Guillain-
Barre syndrome,myasthenia gravis, pemphigus vulgaris, vasculitis, Addison
disease, polymyositis, Bechet syndrome, and polyarteritis nodosa were
grouped with the other autoimmune disease category.
a Excludes first-degree history of MS.
b Chi-squared test of no association.
Table 3 Adjusted Analyses of Reported Family History of
Autoimmune Disease
OR (95% CI) p Value
Any reported family historya 2.27 (1.71, 3.01) <0.001
Diabetes: adult onset 1.80 (1.37, 2.35) <0.001
Diabetes: childhood onset 2.26 (1.22, 4.22) 0.010
Thyroid disease/Hashimoto disease/
Graves disease
1.72 (1.22, 2.43) 0.002
Rheumatoid arthritis 1.63 (1.11, 2.38) 0.012
MSa 4.16 (2.57, 6.75) <0.001
Atopic dermatitis/eczema 0.89 (0.52, 1.51) 0.656
Psoriasis 1.08 (0.63, 1.84) 0.792
Inflammatory bowel disease/Crohn
disease/ulcerative colitis
1.95 (1.09, 3.47) 0.024
Systemic lupus erythematosus 2.16 (1.16, 4.01) 0.015
Other autoimmune disease 1.35 (0.92, 1.99) 0.129
Abbreviation: MS = multiple sclerosis.
Results are based on models adjusting for age, sex, race, ethnicity, and
biological mother’s highest level of education.
a Excludes first-degree history of MS.
Neurology.org/NN Neurology: Neuroimmunology & Neuroinflammation | Volume 8, Number 5 | September 2021 3
Table 4 Analyses of Reported History of Autoimmune Disease Within Various Relative Groups
Unadjusted analyses Adjusted analysesc
Control (N = 709) Case (N = 495) p Value OR (95% CI) p Value
First-degree relatives
Diabetes: adult onset 44 (6.2%) 48 (9.7%) 0.025a 1.41 (0.88, 2.28) 0.156
Diabetes: childhood onset 4 (0.6%) 9 (1.8%) 0.038a 1.80 (0.50, 6.50) 0.369
Thyroid disease/Hashimoto disease/Graves disease 47 (6.6%) 52 (10.5%) 0.016a 1.73 (1.10, 2.72) 0.018
Rheumatoid arthritis 9 (1.3%) 16 (3.2%) 0.019a 2.52 (1.04, 6.10) 0.040
Inflammatory bowel disease/Crohn
disease/ulcerative colitis
12 (1.7%) 11 (2.2%) 0.509a 1.49 (0.64, 3.47) 0.352
Systemic lupus erythematosus 5 (0.7%) 7 (1.4%) 0.249b 2.58 (0.70, 9.52) 0.155
Other autoimmune disease 30 (4.2%) 26 (5.3%) 0.408a 1.14 (0.62, 2.07) 0.675
Second-degree relatives
Diabetes: adult onset 144 (20.3%) 160 (32.3%) <0.001a 1.88 (1.41, 2.51) <0.001
Diabetes: childhood onset 6 (0.8%) 10 (2.0%) 0.080a 2.83 (0.92, 8.69) 0.070
Thyroid disease/Hashimoto disease/Graves disease 41 (5.8%) 31 (6.3%) 0.730a 1.06 (0.63, 1.80) 0.822
Rheumatoid arthritis 38 (5.4%) 45 (9.1%) 0.012a 1.73 (1.07, 2.79) 0.024
MS 8 (1.1%) 15 (3.0%) 0.018a 3.47 (1.36, 8.86) 0.009
Inflammatory bowel disease/Crohn disease/
ulcerative colitis
6 (0.8%) 10 (2.0%) 0.080a 2.39 (0.84, 6.86) 0.104
Systemic lupus erythematosus 8 (1.1%) 9 (1.8%) 0.318a 1.58 (0.58, 4.31) 0.373
Other autoimmune disease 30 (4.2%) 31 (6.3%) 0.114a 1.35 (0.78, 2.35) 0.290
Parents
Diabetes: adult onset 44 (6.2%) 48 (9.7%) 0.025a 1.41 (0.88, 2.28) 0.156
Diabetes: childhood onset 0 (0.0%) 2 (0.4%) 0.169b -d -d
Thyroid disease/Hashimoto disease/Graves
disease
47 (6.6%) 46 (9.3%) 0.088a 1.49 (0.93, 2.37) 0.096
Rheumatoid Arthritis 9 (1.3%) 15 (3.0%) 0.031a 2.34 (0.95, 5.75) 0.063
Inflammatory bowel disease/Crohn disease/
ulcerative colitis
8 (1.1%) 10 (2.0%) 0.210a 2.01 (0.77, 5.24) 0.152
Systemic lupus erythematosus 5 (0.7%) 5 (1.0%) 0.749b 1.77 (0.43, 7.32) 0.430
Other autoimmune disease 27 (3.8%) 24 (4.8%) 0.378a 1.14 (0.61, 2.14) 0.688
Maternal relatives
Diabetes: adult onset 132 (18.6%) 138 (27.9%) <0.001a 1.61 (1.19, 2.17) 0.002
Diabetes: childhood onset 2 (0.3%) 10 (2.0%) 0.005b 8.71 (1.87, 40.43) 0.006
Thyroid disease/Hashimoto disease/Graves disease 80 (11.3%) 76 (15.4%) 0.039a 1.53 (1.05, 2.21) 0.025
Rheumatoid arthritis 45 (6.3%) 51 (10.3%) 0.013a 1.51 (0.97, 2.36) 0.068
MSa 20 (2.8%) 32 (6.5%) 0.002a 2.64 (1.43, 4.89) 0.002
Inflammatory bowel disease/Crohn disease/
ulcerative colitis
12 (1.7%) 14 (2.8%) 0.182a 1.83 (0.82, 4.07) 0.137
Systemic lupus erythematosus 15 (2.1%) 16 (3.2%) 0.229a 1.97 (0.92, 4.26) 0.083
Other autoimmune disease 49 (6.9%) 50 (10.1%) 0.047a 1.32 (0.84, 2.09) 0.230
Continued
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paternal relative analysis for MS, as controls could not have a
history of MS in either parent. Adjusted analyses revealed an
OR of 3.47 of MS among second-degree relatives of patients
with pediatric MS. The OR was 2.64 when restricted to ma-
ternal relatives and 6.37 when restricted to paternal relatives
(Table 4). Adjusted analyses revealed that there was a sta-
tistically significant difference between cases and controls in
prevalence of adult-onset diabetes, childhood-onset diabetes,
and MS in both maternal and paternal secondary relatives.
Rheumatoid arthritis and inflammatory bowel disease had a
higher prevalence in paternal second-degree relatives, but not
maternal. In contrast, thyroid disorders had a higher preva-
lence in maternal second-degree relatives, but not paternal.
Discussion
We sought to identify the prevalence of familial autoimmune
disorders in pediatric MS compared with controls as most
studies have focused on adult MS.12 As children who develop
MS 20–30 years earlier than average age at onset likely have
larger genetic burden and/or environmental exposures than
adults with the disease, the prevalence of autoimmune dis-
orders in their family may be higher than reported for adults
with MS. Studies of a familial history of autoimmune disease
in patients with adult MS have yielded conflicting results.14,15
We have identified a number of autoimmune conditions with
increased prevalence among the family members of patients
with pediatric MS. Of note, 13.7% of patients with pediatric
MS reported a familial history of MS compared with only
4.1% of controls (for whom parents could not have the disease
as specified by study exclusion criteria). In another study,
25.5% of patients with adult MS reported a family history of
MS compared with only 4.1% of controls.14 There were sig-
nificant differences between cases and controls relative to the
frequency of autoimmune diseases (e.g., diabetes and rheu-
matoid arthritis), suggesting some shared risk factors for these
conditions. Indeed, prior work has suggested shared genetic
variants across several autoimmune disorders.15
Notably, not all autoimmune conditions followed this pattern.
There was no increase in the odds of psoriasis and eczema
among family members of pediatric MS cases compared with
controls.
Presumably, the link between various autoimmune diseases
might be genetic and/or environmental exposures that trigger
an aberrant immune response. Although various autoimmune
diseases differ in their target organs and antigens, they share a
common loss of self-tolerance. When analyzing the rate of
familial autoimmune diseases, especially among non–first-
degree relatives, an increased risk of autoimmune conditions
would likely be caused by shared genetic risk factors, rather
than environmental exposures. Understanding families with
increased rates of autoimmune conditions could provide an
opportunity for dissecting out the universal genetic risks for
autoimmunity separate from the genetic risk factors associ-
ated with single conditions. This study found that there was a
higher rate of MS in second-degree relatives among the pa-
tients with pediatric MS compared with controls, and this
difference was most pronounced when the history of MS was
Table 4 Analyses of Reported History of Autoimmune Disease Within Various Relative Groups (continued)
Unadjusted analyses Adjusted analysesc
Control (N = 709) Case (N = 495) p Value OR (95% CI) p Value
Paternal relatives
Diabetes: adult onset 86 (12.1%) 104 (21.0%) <0.001a 1.87 (1.33, 2.63) <0.001
Diabetes: childhood onset 6 (0.8%) 11 (2.2%) 0.046a 2.88 (1.04, 7.97) 0.042
Thyroid disease/Hashimoto disease/Graves disease 17 (2.4%) 20 (4.0%) 0.104a 1.80 (0.90, 3.63) 0.098
Rheumatoid arthritis 15 (2.1%) 26 (5.3%) 0.003a 2.92 (1.44, 5.91) 0.003
MSe 9 (1.3%) 35 (7.1%) <0.001a 6.37 (2.97, 13.66) <0.001
Inflammatory bowel disease/Crohn disease/
ulcerative colitis
7 (1.0%) 13 (2.6%) 0.029a 3.60 (1.32, 9.84) 0.012
Systemic lupus erythematosus 5 (0.7%) 8 (1.6%) 0.132a 2.42 (0.75, 7.85) 0.140
Other autoimmune disease 20 (2.8%) 19 (3.8%) 0.326a 1.33 (0.66, 2.69) 0.425
Abbreviation: MS = multiple sclerosis.
a Chi-squared test of no association.
b Fisher exact test.
c Adjusted analyses are based on logistic models adjusting for age, sex, race, ethnicity, and biological mother’s highest level of education.
d The logistic regression model for childhood-onset diabetes reported in subject’s parents was not stable as none of the controls reported parents with
childhood-onset diabetes.
a Excludes history of MS in mothers as controls with first-degree history of MS are excluded from the study.
e Excludes history of MS in fathers as controls with first-degree history of MS are excluded from the study.
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paternal. Risk of various autoimmune diseases based on par-
ent of origin has been described in numerous genetics studies,
with some conditions having maternal associations (e.g.,
Crohn and juvenile idiopathic arthritis) and others having
paternal associations (e.g., psoriatic arthritis).16,17
Strengths of the study include the prospective collection of data
in multiple centers in the United States representing various
geographical areas, careful case ascertainment, and the number
of pediatric patients recruited. In addition, controls were en-
rolled at the same institutions than cases. Weaknesses include
the survey-based format of data collection (i.e., the lack of
medical confirmation of autoimmune disorders reported by
families) and the potential for a biased sampling of controls
since recruitment occurred at academic pediatric hospitals and
clinics. There are risks for both under- and over-reporting of
family history and the possibility of recall bias among cases.
Although recall bias could definitely lead to an overestimation
of autoimmune diseases in the case cohort, the fact that several
conditions were found to have no statistical difference between
cases and control reduces the bias concern.
The higher rate of autoimmune diseases among family
members of patients with pediatric MS compared with con-
trols, especially the higher rate of MS in second-degree rela-
tives among the patients with pediatric MS, supports the
possibility of shared genetic variants between several auto-
immune diseases andMS. The higher rate of specific disorders
among paternal relatives raises the question of possible im-
printing. The rate of autoimmune disease in this control co-
hort was higher than the general population, particularly in
terms of the percent of participants reporting adult onset
diabetes within their family (i.e., 29%). This represents a
potential bias to the conclusions that could skew the signifi-
cance of the findings, but not likely change the overall con-
clusion. Future studies could be designed to compare the
genetic profiles of various pediatric autoimmune disorders in
an attempt to determine disease specific genes separate from
the genes that dictate risk of losing self-tolerance. Combining
cohort and family history diagnostic data with expanded
genotyping could help establish relative risk of autoimmunity
in families based on genetic predispositions. This would re-
quire expanded genotyping programs beyond traditional trio
designed genetic studies.
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